Melanoma – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Melanoma – Pipeline Review, H1 2018’, provides an overview of the Melanoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Melanoma

– The report reviews pipeline therapeutics for Melanoma by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Melanoma therapeutics and enlists all their major and minor projects

– The report assesses Melanoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Melanoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Melanoma

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Melanoma pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4D Pharma PLC

4P-Pharma SAS

4SC AG

AB Science SA

AbbVie Inc

Abivax SA

Adaptimmune Therapeutics Plc

Aduro BioTech Inc

Advenchen Laboratories LLC

Aeglea BioTherapeutics Inc

Affichem SA

AGV Discovery SAS

AIMM Therapeutics BV

Alkermes Plc

Allergy Therapeutics Plc

Alligator Bioscience AB

Altor BioScience Corp

Amgen Inc

Angimmune LLC

Antibe Therapeutics Inc

Antigen Express Inc

APEIRON Biologics AG

Apexigen Inc

Aphios Corp

Aposense Ltd

Aprea AB

Aptose Biosciences Inc

Arcus Biosciences Inc

ARMO Biosciences Inc

Array BioPharma Inc

Asana BioSciences LLC

Astex Pharmaceuticals Inc

Atreca Inc

aTyr Pharma Inc

Aurigene Discovery Technologies Ltd

Autolus Ltd

Basilea Pharmaceutica Ltd

Batu Biologics Inc

Bayer AG

BeiGene Ltd

Beijing Kawin Technology Share-Holding Co Ltd

Bellicum Pharmaceuticals Inc

BerGenBio ASA

Biocad

Bio-Cancer Treatment International Ltd

Biogazelle NV

Biohaven Pharmaceutical Holding Company Ltd

BioLineRx Ltd

Bionomics Ltd

BioNTech AG

Biothera Pharmaceutical Inc

Biovista Inc

Boehringer Ingelheim GmbH

Boston Biomedical Inc

BrightPath Biotherapeutics Co Ltd

Bristol-Myers Squibb Co

Calithera Biosciences Inc

Can-Fite BioPharma Ltd

CBT Pharmaceuticals Inc

CCRP Therapeutics GmbH

Celgene Corp

Celldex Therapeutics Inc

Cellestia Biotech AG

Celprogen Inc

Celyad SA

Checkmate Pharmaceuticals Inc

Checkpoint Therapeutics Inc

Chipscreen Biosciences Ltd

Chugai Pharmaceutical Co Ltd

Corvus Pharmaceuticals Inc

Curevac AG

CytomX Therapeutics Inc

Cytori Therapeutics Inc

CytoVac AS

Cytune Pharma SAS

CyTuVax BV

CZ BioMed Corp

Daiichi Sankyo Co Ltd

Debiopharm International SA

DEKK-TEC Inc

DNAtrix Inc

Dynavax Technologies Corp

Eisai Co Ltd

Eli Lilly and Co

Elsalys Biotech SA

Ensol Biosciences Inc

EntreChem SL

eTheRNA Immunotherapies NV

Exelixis Inc

Exicure Inc

F. Hoffmann-La Roche Ltd

Faron Pharmaceuticals Oy

Fountain Biopharma Inc

Galapagos NV

Galderma SA

Galectin Therapeutics Inc

Genelux Corp

Genentech Inc

Genexine Inc

Genmab A/S

Genocea Biosciences Inc

GlaxoSmithKline Plc

GTx Inc

Hadasit Medical Research Services and Development Ltd

Hanmi Pharmaceuticals Co Ltd

Harbin Gloria Pharmaceuticals Co Ltd

Heat Biologics Inc

Hemispherx Biopharma Inc

Hercules Pharmaceuticals BV

Histogen Inc

HitGen LTD

Horizon Pharma Plc

Humanigen Inc

ID Pharma Co Ltd

Idera Pharmaceuticals Inc

Ignyta Inc

Immodulon Therapeutics Ltd

Immune Design Corp

Immune Response BioPharma Inc

Immunicum AB

Immunocore Ltd

ImmunoGen Inc

Immunomedics Inc

Immutep Ltd

Imugene Ltd

Incyte Corp

Infinity Pharmaceuticals Inc

Inovio Pharmaceuticals Inc

InteRNA Technologies BV

IO Biotech ApS

Iovance Biotherapeutics Inc

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Jounce Therapeutics Inc

Karus Therapeutics Ltd

Karyopharm Therapeutics Inc

Kineta Inc

Kite Pharma Inc

Kringle Pharma Inc

K-Stemcell Co Ltd

Leap Therapeutics Inc

Lentigen Technology Inc

Lixte Biotechnology Holdings Inc

Loxo Oncology Inc

Lupin Ltd

Lytix Biopharma AS

MacroGenics Inc

Madrigal Pharmaceuticals Inc

MaxiVAX SA

MediaPharma SRL

Medicenna Therapeutics Corp

MediciNova Inc

MedImmune LLC

Medy-Tox Inc

MELEMA Pharma GmbH

Merck & Co Inc

Merck KGaA

MetaMax Ltd

Moderna Therapeutics Inc

Molecular Templates Inc

Moleculin Biotech Inc

Morphotek Inc

NanoVector Inc

NantKwest Inc

Nektar Therapeutics

Neonc Technologies Inc

Nerviano Medical Sciences Srl

NewLink Genetics Corp

NormOxys Inc

Northwest Biotherapeutics Inc

Novartis AG

Omeros Corp

Oncology Research International Ltd

Oncolys BioPharma Inc

OncoNOx ApS

OncoResponse Inc

OncoSec Medical Inc

OncoTartis Inc

Oncovir Inc

Opsona Therapeutics Ltd

Oxford BioTherapeutics Ltd

Pacific Northwest Biotechnology LLC

Patrys Ltd

PCI Biotech Holding ASA

PepVax Inc

Pfizer Inc

Pharmicell Co Ltd

Philogen SpA

PinCell srl

Pivotal BioSciences Inc

Plexxikon Inc

Polaris Pharmaceuticals Inc

Polyplus-Transfection SA

Primevax Immuno Oncology Inc

Promore Pharma

Propanc Biopharma Inc

Provectus Biopharmaceuticals Inc

Provenance Biopharmaceuticals Corp

Qu Biologics Inc

Rafael Pharmaceuticals Inc

Reata Pharmaceuticals Inc

Recombio SL

Regeneron Pharmaceuticals Inc

Replimune Ltd

Rexahn Pharmaceuticals Inc

Rgenix Inc

Rubicon Biotechnology Inc

RXi Pharmaceuticals Corp

Sanofi

SATT North SAS

Scancell Holdings Plc

Seres Therapeutics Inc

SilaGene Inc

Sillajen Biotherapeutics

Sino Biopharmaceutical Ltd

SolaranRx Inc

Sorrento Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd

Susavion Biosciences Inc

SuviCa Inc

Syndax Pharmaceuticals Inc

Synthon Holdings BV

Syntrix Biosystems Inc

Tactiva Therapeutics LLC

Taiga Biotechnologies Inc

Takara Bio Inc

Takis Srl

Targovax ASA

TC BioPharm Ltd

Theravectys SA

Tikcro Technologies Ltd

TILT Biotherapeutics Ltd

Tocagen Inc

Tolero Pharmaceuticals Inc

TREAT U SA

Trillium Therapeutics Inc

UbiVac LLC

Ultimovacs AS

Vaccibody AS

Valo Therapeutics Oy

Vascular Biogenics Ltd

Vault Pharma Inc

Vichem Chemie Research Ltd

Viralytics Ltd

ViraTherapeutics GmbH

VLP Therapeutics LLC

WntResearch AB

X4 Pharmaceuticals Inc

Xencor Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 12

Melanoma Overview 13

Melanoma Therapeutics Development 14

Melanoma Therapeutics Assessment 75

Melanoma Companies Involved in Therapeutics Development 107

Melanoma Drug Profiles 218

Melanoma Dormant Projects 1897

Melanoma Discontinued Products 1929

Melanoma Product Development Milestones 1933

Appendix 1949

List of Tables

List of Tables

Number of Products under Development for Melanoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Melanoma Pipeline by 4D Pharma PLC, H1 2018

Melanoma Pipeline by 4P-Pharma SAS, H1 2018

Melanoma Pipeline by 4SC AG, H1 2018

Melanoma Pipeline by AB Science SA, H1 2018

Melanoma Pipeline by AbbVie Inc, H1 2018

Melanoma Pipeline by Abivax SA, H1 2018

Melanoma Pipeline by Adaptimmune Therapeutics Plc, H1 2018

Melanoma Pipeline by Aduro BioTech Inc, H1 2018

Melanoma Pipeline by Advenchen Laboratories LLC, H1 2018

Melanoma Pipeline by Aeglea BioTherapeutics Inc, H1 2018

Melanoma Pipeline by Affichem SA, H1 2018

Melanoma Pipeline by AGV Discovery SAS, H1 2018

Melanoma Pipeline by AIMM Therapeutics BV, H1 2018

Melanoma Pipeline by Alkermes Plc, H1 2018

Melanoma Pipeline by Allergy Therapeutics Plc, H1 2018

Melanoma Pipeline by Alligator Bioscience AB, H1 2018

Melanoma Pipeline by Altor BioScience Corp, H1 2018

Melanoma Pipeline by Amgen Inc, H1 2018

Melanoma Pipeline by Angimmune LLC, H1 2018

Melanoma Pipeline by Antibe Therapeutics Inc, H1 2018

Melanoma Pipeline by Antigen Express Inc, H1 2018

Melanoma Pipeline by APEIRON Biologics AG, H1 2018

Melanoma Pipeline by Apexigen Inc, H1 2018

Melanoma Pipeline by Aphios Corp, H1 2018

Melanoma Pipeline by Aposense Ltd, H1 2018

Melanoma Pipeline by Aprea AB, H1 2018

Melanoma Pipeline by Aptose Biosciences Inc, H1 2018

Melanoma Pipeline by Arcus Biosciences Inc, H1 2018

Melanoma Pipeline by ARMO Biosciences Inc, H1 2018

Melanoma Pipeline by Array BioPharma Inc, H1 2018

Melanoma Pipeline by Asana BioSciences LLC, H1 2018

Melanoma Pipeline by Astex Pharmaceuticals Inc, H1 2018

Melanoma Pipeline by Atreca Inc, H1 2018

Melanoma Pipeline by aTyr Pharma Inc, H1 2018

Melanoma Pipeline by Aurigene Discovery Technologies Ltd, H1 2018

Melanoma Pipeline by Autolus Ltd, H1 2018

Melanoma Pipeline by Basilea Pharmaceutica Ltd, H1 2018

Melanoma Pipeline by Batu Biologics Inc, H1 2018

Melanoma Pipeline by Bayer AG, H1 2018

Melanoma Pipeline by BeiGene Ltd, H1 2018

Melanoma Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H1 2018

Melanoma Pipeline by Bellicum Pharmaceuticals Inc, H1 2018

Melanoma Pipeline by BerGenBio ASA, H1 2018

Melanoma Pipeline by Bio-Cancer Treatment International Ltd, H1 2018

Melanoma Pipeline by Biocad, H1 2018

Melanoma Pipeline by Biogazelle NV, H1 2018

Melanoma Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2018

Melanoma Pipeline by BioLineRx Ltd, H1 2018

Melanoma Pipeline by Bionomics Ltd, H1 2018

Melanoma Pipeline by BioNTech AG, H1 2018

Melanoma Pipeline by Biothera Pharmaceutical Inc, H1 2018

Melanoma Pipeline by Biovista Inc, H1 2018

Melanoma Pipeline by Boehringer Ingelheim GmbH, H1 2018

Melanoma Pipeline by Boston Biomedical Inc, H1 2018

Melanoma Pipeline by BrightPath Biotherapeutics Co Ltd, H1 2018

Melanoma Pipeline by Bristol-Myers Squibb Co, H1 2018

Melanoma Pipeline by Calithera Biosciences Inc, H1 2018

Melanoma Pipeline by Can-Fite BioPharma Ltd, H1 2018

Melanoma Pipeline by CBT Pharmaceuticals Inc, H1 2018

Melanoma Pipeline by CCRP Therapeutics GmbH, H1 2018

Melanoma Pipeline by Celgene Corp, H1 2018

Melanoma Pipeline by Celldex Therapeutics Inc, H1 2018

Melanoma Pipeline by Cellestia Biotech AG, H1 2018

List of Figures

List of Figures

Number of Products under Development for Melanoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports